Mosaic ImmunoEngineering Inc
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
CPMVStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year Ended December 31, 2023 | For the Year Ended December 31, 2022 | |
|---|---|---|
| Operating expenses: | ||
| Research and development | $435,449 | $1,048,457 |
| General and administrative | 964,319 | 1,579,065 |
| Total operating expenses | 1,399,768 | 2,627,522 |
| Loss from operations | (1,399,768) | (2,627,522) |
| Other income (expense): | ||
| Gain on redemption of preferred stock of Holocom | 433,000 | 343,000 |
| Interest income | 3,408 | 33 |
| Change in valuation of derivative liability | 46,700 | 57,600 |
| Non-cash interest expense on convertible notes | (73,333) | (69,738) |
| Accretion to redemption value on convertible notes | (15,842) | (81,843) |
| Total other income, net | 393,933 | 249,052 |
| Loss before provision for income taxes | (1,005,835) | (2,378,470) |
| Provision for income taxes | 2,400 | 2,400 |
| Net loss | $(1,008,235) | $(2,380,870) |
| Basic loss per common share | $(0.14) | $(0.33) |
| Diluted loss per common share | $(0.14) | $(0.33) |
| Weighted average number of common shares outstanding – basic and diluted | 7,236,447 | 7,235,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.